Some previous studies reported the relationship between the mutation status of epidermal growth factor receptor (EGFR) gene and serum carcinoembryonic antigen (CEA) level in advanced or recurrent lung adenocarcinomas. In the present study, this relationship was examined in resected lung adenocarcinomas. One hundred thirty five resected lung adenocarcinoma patients were reviewed retrospectively. Mutations of the EGFR gene were detected in 64 of the 135 patients, the most common being deletions in exon 19 and the L858R mutations in exon 21. The patients with normal serum CEA level had favorable prognosis, whereas those with high had poor prognosis. The 5-year survival of the patients with EGFR mutationnegative was significantly worse than that of the patients with EGFR mutation-positive. Both univariate and multivariate analyses indicated an independent prognostic impact of the combined use of serum CEA level and the status of EGFR mutation. There was no difference in the rate of EGFR gene mutations according to the serum CEA level. Furthermore we also failed to find the differences in the serum CEA level based on the EGFR mutation status. The rate of deletions in exon 19 and/or the L858R mutation in exon 21 was not also related to the serum CEA level. In conclusions we failed to find the relationship between the serum CEA level and the EGFR mutation status in resected lung adenocarcinomas.
Introduction
It is well accepted that activating mutations in the epidermal growth factor receptor (EGFR) in non-small cell lung carcinoma (NSCLC) are associated significantly with responsiveness to EGFR tyrosine kinase inhibitors (TKI) 1) . However it is often difficult to obtain sufficient amounts of tumor samples from NSCLC patients. A recent study reported that the molecular analysis of circulating tumor cells from the peripheral blood of patients with lung cancer was useful in monitoring changes in epithelial tumor genotypes during the course of treatment 2) . However these methods are expensive and available only as research tools. Therefore, the identification of clinical parameters that can serve as surrogates for EGFR mutation may prove useful when mutational analysis is not feasible.
Previous reports showed that serum carcinoembryonic antigen (CEA) level was a significant predictor of sensitivity and survival in patients treated with gefitinib [3] [4] [5] . Although the reason for this correlation is not unknown in detail, Shoji, et al. 6) reported that the rate of EGFR gene mutation is significantly increased as the serum CEA level increases in recurrent NSCLC. However the study population of these studies was patients with advances diseases or patients treated with gefitinib. Therefore, in the present study, we investigated the relationship between serum CEA level and EGFR mutation status. In addition, we analyzed the association between serum CEA level and EGFR mutation status and the prognosis to find useful markers for lung cancer.
Patients and Methods
Consecutive lung adenocarcinoma patients who had undergone surgical resection from 2004 through 2011 were included in this study. Patients who did not undergo EGFR mutation examination, died of other diseases within 5 years after surgery or were lost to follow-up were excluded. There were 135 lung adenocarcinoma patients who fulfilled the inclusion criteria. The preoperative serum CEA level was measured using the two-site immunoenzymometric assay; the normal upper limit for this assay was 5.0 ng/mL. Surgical samples were analyzed for EGFR mutation using Cycleave polymerase chain reaction (PCR) method 7) by SRL Inc. (Tokyo, Japan). Pathological (p) tumor-node-metastasis (TNM) staging was recorded in all patients based on the 7th edition of the American Joint Committee on Cancer (AJCC)/ International Union Against Cancer (UICC) classification. The baseline characteristics are summarized in Table 1 . Follow-up information, including cause of death, was ascertained through a review of clinic notes and direct or family contact. The survival curves of the patients were plotted by using the Kaplan-Meier method and analyzed using the log-rank test. Fischer's exact test with Yates' correction was used to correlate clinicopathological parameters. Cox regression hazard model was used for univariate and multivariate analyses. Statistical calculations were conducted with JMP (SAS Institute Inc. Cary, NC, USA) and values of p less than 0.05 were accepted as being significant.
Results
Mutations of the EGFR gene were detected in 64 of 135 patients. A deletion in exon 19 was observed in 27 patients. Among them, most popular type was E746-A750 deletion (19/27). Point mutations of L858R (2573T>G) in exon 21 were found in 35 patients. Two patients had the mutation in exon 18 (G719X). Adjuvant therapy was performed for 39 patients, and 14 patients received EGFR-TKI treatment for their recurrences. As shown in Table 1 , the number of patients with high serum CEA level was 44 (32.59%). The relationship between pStage and serum CEA / EGFR mutation status were shown in Fig. 1 . There was a trend towards an association between pStage and serum CEA level, but this did not reach statistical significance.
The survival curve based on preoperative serum CEA level is shown in Fig. 2A and the 5-year survival of the patients with high and normal serum CEA level was 62.19% or 87.26%, respectively (p=0.002). Similarly, as shown in Fig. 2B , the 5-year survival of the patients with EGFR mutation-negative was significantly worse than that of the patients with EGFR mutation-positive (72.54% vs. 88.55%, p=0.038).
The survival curve based on the combined use of serum CEA level and the status of EGFR mutation was shown in Fig. 3 . The 5-year survival of patients with both normal serum CEA level and EGFR mutation-positive was 100% (p=0.002), whereas there were no significant differences in the 5-year survival among other groups. The results of univariate analysis are summarized in Table 2 . The gender, smoking status, pStage, pT srarus, pN status and the combined use of serum CEA level and EGFR mutation status (normal serum CEA level and EGFR mutation-positive vs. others) were related to patients' prognosis. The results of multivariate analysis including all variables for which p<0.05 on univariate analysis are also summarized in Table 2 . Of the variables that were included in the multivariate analysis, pN status and the combined use of serum CEA level and EGFR mutation status were independent prognostic determinants.
The rate of EGFR gene mutations according to the serum CEA level was shown in Fig. 4 . There was no difference in the rate of EGFR gene mutations and the serum CEA level (p=0.22). The rate of deletions in exon 19 and/or the L858R mutation in exon 21 was not also related to the serum CEA level (p=0.22).
Serum CEA level based on EGFR mutation status was shown in Fig. 5 . We also failed to find the relationship between the serum CEA level and the EGFR mutation status. There was also no difference in serum CEA level among patients with EGFR mutation-negative, the deletions in exon 19 and the L858R mutation (EGFR mutation-negative vs. EGFR mutation-positive: p=0.44, EGFR mutation-negative vs. exon 19 deletion: p= 0.19, EGFR mutation-negative vs. L858R mutation: p= 0.40, Fig. 5A, B) . 
Discussion
The CEA is an important marker for malignant tumors, including NSCLC. High serum CEA levels have been identified as an unfavorable prognostic factor in NSCLC, especially in adenocarcinoma [8] [9] [10] . Our results also showed the prognostic significance of preoperative serum CEA level. On the contrary, Okamoto et al. 3) and Jung et al. 5) reported that patients treated with EGFR-TKI with high pretreatment levels of CEA had a longer survival and a better response than those with low CEA levels. They attributed this to a possible anti-apoptotic signal of the mutant EGFR pathway that may elevate the expression level of CEA protein 3, 5) . However, as described above, high serum CEA level is widely accepted as a poor prognostic indicator [8] [9] [10] . Tanaka et al. 11 ) also described no association between serum CEA levels and survival of the NSCLC patients in EGFR mutationpositive patients treated with EGFR-TKIs. Since the study population of previous studies [3] [4] [5] [6] was limited to the patients treated with EGFR-TKI, their study population might be a quite special group of NSCLC.
We also showed that the 5-year survival of the patients with EGFR mutation-negative was significantly worse than that of the patients with EGFR mutation-positive. Our results are similar to the data of previous studies 12, 13) . The reasons for the favorable prognosis are considered as follows: the EGFR gene mutations themselves provide good prognosis (prognostic factor), good responsiveness to EGFR TKI, and good responsiveness to cytotoxic antitumor drugs 12, 13) . Moreover we showed the prognostic significance of the combined use of serum CEA level and EGFR mutation status. Therefore the mechanism of prognostic effect of serum CEA level and EGFR mutation status might not be identical.
In the present results, we failed to find the relationship between the serum CEA level and the EGFR mutation status in resected lung adenocarcinomas. Furthermore our results of the combined use of serum CEA level and EGFR mutation showed that the 5-year survival of patients with both normal serum CEA level and EGFR mutation-positive was significantly favorable when compared to others. From this finding, we cannot consider that there is a relationship between the mechanism of serum CEA elevation and EGFR mutation. Jung et al. 5 ) also failed to find that the relationship between the status of EGFR mutation and serum CEA levels in patients with advanced NSCLC receiving EGFR-TKI. On the contrary, Shoji et al. 6) reported that the rate of EGFR gene mutation is significantly increased as the serum CEA level increases. However their study was limited to the patients with recurrent adenocarcinomas 6) . Therefore one of possible reasons for the different results might be due to differences in patients' population.
There are some studies that showed a correlation between CEA and EGFR expression in other cancers. Singh et al. 14) demonstrated that EGFR and CEA were associated with the production of liver metastases in human colon carcinoma cells. Abdel-Azizz et al. 15) reported that a double positive status of CEA and EGFR expression was found in the majority of patients (81%) with colorectal cancers. Shoji et al. 6) quoted these papers for the discussion of their results about the relationship between the status of EGFR mutation and serum CEA level. However the expression of EGFR protein and the mutation of EGFR gene are not identical phenomenon.
Detection of an EGFR mutation is important factor but difficult due to the limited amount of available tissue. Therefore, another easily available biomarker that can improve the prediction of response to EGFR-TKI is needed. From our results, serum CEA level cannot be a useful biomarker for the detection of EGFR mutation. Further clinical studies will be necessary to find the useful and easily available biomarkers for the detection of EGFR mutation.
In conclusion, we failed to find the relationship be- tween the serum CEA level and the EGFR mutation status in resected lung adenocarcinomas.
